Flagship record · Pramlintide

Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.

systematic review meta analysisreview level evidencesecondary multi agent subject

Scientific attribution

The source synthesizes evidence across multiple specifically named agents.

PMID: 25590213
DOI: 10.1210/jc.2014-3421
Sample size: 696
Population / model: We included 257 randomized trials (54 different drugs; 84 696 patients enrolled).

Intervention / comparator

We included randomized trials that compared an a priori selected list of drugs to placebo and measured weight change.

Outcomes

Various drugs affect body weight as a side effect.
Weight loss was associated with the use of metformin (1.1 kg), acarbose (0.4 kg), miglitol (0.7 kg), pramlintide (2.3 kg), liraglutide (1.7 kg), exenatide (1.2 kg), zonisamide (7.7 kg), topiramate (3.8 kg), bupropion (1.3 kg), and fluoxetine (1.3 kg).
Data are provided to guide the choice of drug when several options exist and institute preemptive weight loss strategies when obesogenic drugs are prescribed.

Key findings

Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide (2.6 kg), glipizide (2.2 kg), sitagliptin (0.55 kg), and nateglinide (0.3 kg).
Weight loss was associated with the use of metformin (1.1 kg), acarbose (0.4 kg), miglitol (0.7 kg), pramlintide (2.3 kg), liraglutide (1.7 kg), exenatide (1.2 kg), zonisamide (7.7 kg), topiramate (3.8 kg), bupropion (1.3 kg), and fluoxetine (1.3 kg).
Several drugs are associated with weight change of varying magnitude.

Limitations

We extracted data in duplicate and assessed the methodological quality using the Cochrane risk of bias tool.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Loading research intelligence

Preparing the structured Flagship evidence library.

Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.

systematic review meta analysisreview level evidencesecondary multi agent subject

Scientific attribution

The source synthesizes evidence across multiple specifically named agents.

PMID

25590213

DOI

10.1210/jc.2014-3421

Sample size

696

Population / model

We included 257 randomized trials (54 different drugs; 84 696 patients enrolled).

Intervention / comparator

We included randomized trials that compared an a priori selected list of drugs to placebo and measured weight change.

Outcomes

Various drugs affect body weight as a side effect.
Weight loss was associated with the use of metformin (1.1 kg), acarbose (0.4 kg), miglitol (0.7 kg), pramlintide (2.3 kg), liraglutide (1.7 kg), exenatide (1.2 kg), zonisamide (7.7 kg), topiramate (3.8 kg), bupropion (1.3 kg), and fluoxetine (1.3 kg).
Data are provided to guide the choice of drug when several options exist and institute preemptive weight loss strategies when obesogenic drugs are prescribed.

Key findings

Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide (2.6 kg), glipizide (2.2 kg), sitagliptin (0.55 kg), and nateglinide (0.3 kg).
Weight loss was associated with the use of metformin (1.1 kg), acarbose (0.4 kg), miglitol (0.7 kg), pramlintide (2.3 kg), liraglutide (1.7 kg), exenatide (1.2 kg), zonisamide (7.7 kg), topiramate (3.8 kg), bupropion (1.3 kg), and fluoxetine (1.3 kg).
Several drugs are associated with weight change of varying magnitude.

Limitations

We extracted data in duplicate and assessed the methodological quality using the Cochrane risk of bias tool.